Dag N.
- Country
- Sweden
- Department
- Institutionen för medicinska vetenskaper; Neurologi
Research Overview
- An Observational Study of the Efficacy and Usability of OraFID Dispensing Device and Digital Application for Carbidopa and Levodopa Administration in Parkinson's Disease Patients
- Phase II Open-Label Extension Study of Oral Montelukast Sodium for Disease Modification in Mild-Moderate Parkinson’s Disease (MONTPARK_OLE)
- Evaluation of Montelukast Sodium as a Disease-Modifying Agent in Early to Moderate Parkinson's Disease: A Double-Blind, Randomized, Placebo-Controlled Phase II Trial
Data & Insights
Has run more than one trial at 5 of 14 partner sites.
Specializations
Neurological Disorders
Specialized focus on investigating therapeutic approaches for Parkinson's disease, particularly in early to moderate stages of the condition.
- Disease Progression Management
- Movement Disorders
- Neurodegenerative Conditions
Investigates innovative treatment modalities aimed at modifying disease progression in neurological disorders.
Therapeutic Innovation
Explores the potential of repurposed medications in treating neurodegenerative conditions, with particular attention to novel applications in movement disorders.
- Drug Repurposing
- Disease-Modifying Therapies
- Clinical Applications
Focuses on identifying new therapeutic possibilities for established medications in neurological conditions.
Clinical Assessment
Conducts research in therapeutic evaluation methodologies for neurodegenerative disorders, emphasizing controlled clinical investigations.
- Treatment Efficacy
- Disease Monitoring
- Clinical Outcomes
Specializes in evaluating therapeutic interventions for neurological conditions through systematic clinical assessment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.